EUVIMEDEUVIMED entdecken
Crossref

Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer

Se-Il Go, Won Sup Lee, Gyeong-Won Lee, Jung Hun Kang, Myoung Hee Kang, Haa-Na Song, Anna Lee, Un Seok Lee, Hye Jung Choi, Hoon-Gu Kim

Chemotherapy · 2014 · 60 (4) · 267-273

DOI: 10.1159/000381636 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemotherapy, online erschienen am 28.04.2015. Verfasst von Se-Il Go und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University School of Medicine, Ji…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy and tolerance of a gemcitabine and vinorelbine (GV) combination as salvage therapy have not been reported in elderly patients with advanced non-small cell lung cancer (NSCLC).

Methods

We reviewed elderly patients with advanced NSCLC who had disease progression after one or more chemotherapy regimens, at least one including platinum, and then who were treated with GV as the salvage therapy.

Results

In total 40 patients were analyzed. GV was at least the third-line chemotherapy in 24 patients (60.0%). Only 2 patients (5.0%) experienced grade 3 febrile neutropenia. Nonhematologic toxicities were generally mild and there was no treatment-related mortality. Among 29 patients evaluable for treatment response, 10 (34.5%) and 9 (31.0%) achieved a partial response and stable disease, respectively. The median overall survival was 10.3 months and the median progression-free survival was 3.1 months.

Conclusions

GV in combination is an effective and tolerable salvage regimen in elderly and heavily pretreated patients with advanced NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDeoxycytidineFemaleFollow-Up StudiesHumansLung NeoplasmsMalePlatinum CompoundsRetrospective StudiesSurvival RateTreatment OutcomeVinblastineVinorelbineGemcitabine

Substanzen

Platinum CompoundsDeoxycytidineVinblastineVinorelbineGemcitabine

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, South Korea.

Zitieren

APA

Go, S. I., Lee, W. S., Lee, G. W., Kang, J. H., Kang, M. H., Song, H. N., Lee, A., Lee, U. S., Choi, H. J., & Kim, H. G. (2014). Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer. Chemotherapy, 60(4), 267-273. https://doi.org/10.1159/000381636

Vancouver

Go SI, Lee WS, Lee GW, Kang JH, Kang MH, Song HN, et al. Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer. Chemotherapy. 2014;60(4):267-273. doi:10.1159/000381636

BibTeX
@article{Go2014,
  author = {Go, Se-Il and Lee, Won Sup and Lee, Gyeong-Won and Kang, Jung Hun and Kang, Myoung Hee and Song, Haa-Na and Lee, Anna and Lee, Un Seok and Choi, Hye Jung and Kim, Hoon-Gu},
  title = {Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer},
  journal = {Chemotherapy},
  year = {2014},
  volume = {60},
  number = {4},
  pages = {267--273},
  doi = {10.1159/000381636}
}
Kostenlos starten →